The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut

BACKGROUND/OBJECTIVE: Nunavut has the highest hospitalization rates for respiratory syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year <1 year of age. Palivizumab was implemented in Nunavut primarily for premature infants, or those with hemodynamically significant ca...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Banerji, Anna, Panzov, Vladimir, Young, Michael, Lee, Bonita E, Mamdani, Muhammad, Giles, B Louise, Dennis, Marguerite, Morel, Johanne, Bisson, Danny, Paes, Bosco A, Hui, Charles, Mahony, Jim
Format: Artigo
Idioma:Inglês
Publicat: Pulsus Group Inc 2014
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4128465/
https://ncbi.nlm.nih.gov/pubmed/24367792
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars